CAMBRIDGE, MA—BioMed Realty’s recent acquisition of 7.2-acre Assembly Square site, which will be developed in phases and represents a total of 1.3 million square feet of purpose-built innovation space for research, technology, and life science tenants, is a giant strategic move by BioMed Realty in Boston’s booming life sciences real estate market.
Earlier this month, BioMed Realty also announced the acquisition of 601 Congress Street in Boston. The 482,000-square-foot LEED Platinum office building, which previously served as John Hancock’s corporate headquarters, provides a life science conversion opportunity.
In an exclusive video interview with Boston Real Estate Times, Bill Kane, BioMed Realty’s Executive Vice President, East Coast and United Kingdom Markets, talks about these two acquisitions, future plans and the strength of booming life sciences real estate market in Greater Boston and around the country.
To watch the full interview, please click here, or on the image below.
Mr. Kane has served as Executive Vice President of BioMed’s East Coast and U.K. Markets since January 2019. For over 20 years, he has served in various leasing and development capacities in Massachusetts, New York, Maryland, New Jersey, and Pennsylvania.
Prior to joining BioMed in October 2008, he was responsible for the development of R&D, hospital, and office real estate development projects for the Fallon Company, Davis Marcus Partners, Lyme Properties, and Turner Construction.
He received his Bachelor of Science Degree from Tufts University and Master of Business Administration Degree and Master of Science Degree from Boston University.
BioMed Realty, a Blackstone portfolio company, is a leading provider of real estate solutions to the life science and technology industries.
As of December 31, 2020, BioMed owns and operates high quality life science real estate comprising 11.4 million square feet concentrated in leading innovation markets throughout the United States and United Kingdom, including Boston/Cambridge, San Francisco, San Diego, Seattle and Cambridge, U.K. In addition, BioMed maintains a premier development platform with 2.8 million square feet of Class A properties in active construction to meet the growing demand of the life science industry.
